Human trial / meta-analysis — Includes human trial or meta-analysis evidence.
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered from 1 recent study; not yet curated.
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
6 published studies by what they were done in. Lab and animal findings often do not carry over to people.
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Tracking 6 published studies of Temozolomide: 1 in humans, 1 in the lab, 4 reviews/other.
Reported direction across studies: 2 positive, 1 mixed, 3 inconclusive.
Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.
These counts summarize what the studies reported; they are not a measure of whether Temozolomide works.
Cancers named in these studies
Med (New York, N.Y.) · Sep 2025 · Phase 2, single-arm with case-matched control comparison
This phase 2 clinical trial enrolled 31 patients with newly diagnosed glioblastoma after chemoradiation to test adding pembrolizumab to TTFields plus temozolomide. Among 26 patients treated per protocol, median progression-free survival was 12.0 vs. 5.8 months (HR 0.377; p = 0.0026) and median overall survival was 24.8 vs. 14.6 months (HR 0.522; p = 0.0477) compared to case-matched controls. Patients who had biopsy only showed larger PFS and OS benefits than those with maximal resection. Immune analyses suggested TTFields induced a T1IFN-driven clonal T cell expansion while pembrolizumab supported adaptive replacement and sustained T cell activation; severe treatment-related adverse events were reported as 7.5%.
Reported effects: median PFS 12 mo · PFS hazard ratio 0.377 [0.217–0.653], p=0.0026 · +7 more
Studied with: pembrolizumab, temozolomide.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
Cancers · Apr 2024 · review
This narrative review summarizes emerging therapeutic approaches for glioblastoma, noting the disease's high heterogeneity and poor prognosis (approximately 12–18 months survival). It discusses limitations of conventional therapies (temozolomide, radiation, surgery) and reviews targeted pathways (PI3K, NF-kB, JAK-STAT, CK2, WNT, NOTCH, Hedgehog, TGF-beta) as well as oncolytic viruses and nanomaterials and their potential to improve blood–brain barrier penetration.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Developmental neuroscience · Jan 2023 · narrative review
This narrative review examines the role of primary cilia on normal brain cells and glioblastoma (GBM) cells in the context of therapy with temozolomide (TMZ) and tumor treating fields (TTFields). The authors summarize evidence that GBM cilia can be exploited to promote tumor growth and treatment resistance, and they review how TMZ and TTFields affect ciliogenesis. They note recent findings of differential regulation of GBM ciliogenesis by TTFields versus TMZ and recommend intracranial TTFields models to test prognostic capacity.
Studied with: tumor treating fields (TTFields), temozolomide (TMZ).
Addresses how primary cilia modulate glioblastoma cell responses to two anticancer modalities (TMZ chemotherapy and TTFields), relevant to tumor sensitivity and resistance.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Redox biology · Oct 2022 · cell culture mechanistic study
This laboratory study looked at TRIM7 in human glioblastoma cells. The authors found that lowering TRIM7 reduced cell growth and increased cell death, while increasing TRIM7 had the opposite effect. They also reported that TRIM7 reduced NCOA4-related ferritinophagy and ferroptosis, and that removing TRIM7 made the cells more sensitive to temozolomide.
Studied with: temozolomide.
The study examines a molecular mechanism in glioblastoma cells and how TRIM7 affects cell growth, ferroptosis, and temozolomide sensitivity.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
International journal of molecular sciences · Jun 2022 · narrative review
This is a narrative review summarizing current glioblastoma management and future research directions. It states standard care remains maximal safe resection plus radiotherapy and temozolomide, with bevacizumab used in the recurrent setting, and reviews investigational approaches including immunotherapy, new synthetic molecules, natural compounds at preclinical stages, and glioblastoma stem cell inhibition. The authors conclude that prognosis remains poor and that combined strategies and improved delivery methods may enhance standard therapy in the future.
Studied with: maximal safe surgical resection, radiotherapy, temozolomide, bevacizumab, immunotherapy, synthetic molecules, natural compounds, glioblastoma stem cell inhibition.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Neurosurgery clinics of North America · Apr 2021
This review summarizes novel radiation approaches for glioblastoma. It states the standard care is surgery followed by radiotherapy to 60 Gy with concurrent and adjuvant temozolomide with or without tumor-treating fields, and describes advanced imaging, particle therapies (protons, carbon ions, boron neutron capture), various re-irradiation techniques, and FLASH radiotherapy as promising areas under evaluation.
Studied with: temozolomide, tumor-treating fields.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
The latest additions to Temozolomide's evidence base, and anything that's been retracted.
Recently addedWhere at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Includes human trial or meta-analysis evidence.
Largest credible effect: PFS hazard ratio 0.377 [0.217–0.653], p=0.0026 PMID 40466642 · median-survival values 12–31.6 across 4 studies
Most authoritative study: Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study
No primary experimental studies yet.
Most authoritative study: Cilia at the Crossroads of Tumor Treating Fields and Chemotherapy
9 ongoing · 21 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.